169 related articles for article (PubMed ID: 37964543)
21. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.
Meric-Bernstam F; Johnson AM; Dumbrava EEI; Raghav K; Balaji K; Bhatt M; Murthy RK; Rodon J; Piha-Paul SA
Clin Cancer Res; 2019 Apr; 25(7):2033-2041. PubMed ID: 30442682
[TBL] [Abstract][Full Text] [Related]
22. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.
Pignochino Y; Sarotto I; Peraldo-Neia C; Penachioni JY; Cavalloni G; Migliardi G; Casorzo L; Chiorino G; Risio M; Bardelli A; Aglietta M; Leone F
BMC Cancer; 2010 Nov; 10():631. PubMed ID: 21087480
[TBL] [Abstract][Full Text] [Related]
23. Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma.
Cenaj O; Ligon AH; Hornick JL; Sholl LM
Am J Clin Pathol; 2019 Jun; 152(1):97-108. PubMed ID: 31115453
[TBL] [Abstract][Full Text] [Related]
24. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study.
Meric-Bernstam F; Beeram M; Hamilton E; Oh DY; Hanna DL; Kang YK; Elimova E; Chaves J; Goodwin R; Lee J; Nabell L; Rha SY; Mayordomo J; El-Khoueiry A; Pant S; Raghav K; Kim JW; Patnaik A; Gray T; Davies R; Ozog MA; Woolery J; Lee KW
Lancet Oncol; 2022 Dec; 23(12):1558-1570. PubMed ID: 36400106
[TBL] [Abstract][Full Text] [Related]
25. Human epidermal growth factor receptor 2-positive digestive tumors.
Wagner AD; Özdemir BC; Rüschoff J
Curr Opin Oncol; 2019 Jul; 31(4):354-361. PubMed ID: 31170116
[TBL] [Abstract][Full Text] [Related]
26. HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy.
Takegawa N; Yonesaka K
Clin Colorectal Cancer; 2017 Dec; 16(4):247-251. PubMed ID: 28363756
[TBL] [Abstract][Full Text] [Related]
27. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.
Richman SD; Southward K; Chambers P; Cross D; Barrett J; Hemmings G; Taylor M; Wood H; Hutchins G; Foster JM; Oumie A; Spink KG; Brown SR; Jones M; Kerr D; Handley K; Gray R; Seymour M; Quirke P
J Pathol; 2016 Mar; 238(4):562-70. PubMed ID: 26690310
[TBL] [Abstract][Full Text] [Related]
28. Emergence of
Subramanian J; Katta A; Masood A; Vudem DR; Kancha RK
Oncologist; 2019 Dec; 24(12):e1303-e1314. PubMed ID: 31292270
[TBL] [Abstract][Full Text] [Related]
29. Update on HER2 testing for breast and upper gastrointestinal tract cancers.
Ross JS
Biomark Med; 2011 Jun; 5(3):307-18. PubMed ID: 21657840
[TBL] [Abstract][Full Text] [Related]
30. EGFR and HER2 expression in advanced biliary tract cancer.
Harder J; Waiz O; Otto F; Geissler M; Olschewski M; Weinhold B; Blum HE; Schmitt-Graeff A; Opitz OG
World J Gastroenterol; 2009 Sep; 15(36):4511-7. PubMed ID: 19777609
[TBL] [Abstract][Full Text] [Related]
31. Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer.
Kloth M; Ruesseler V; Engel C; Koenig K; Peifer M; Mariotti E; Kuenstlinger H; Florin A; Rommerscheidt-Fuss U; Koitzsch U; Wodtke C; Ueckeroth F; Holzapfel S; Aretz S; Propping P; Loeffler M; Merkelbach-Bruse S; Odenthal M; Friedrichs N; Heukamp LC; Zander T; Buettner R
Gut; 2016 Aug; 65(8):1296-305. PubMed ID: 26001389
[TBL] [Abstract][Full Text] [Related]
32. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
Plum PS; Gebauer F; Krämer M; Alakus H; Berlth F; Chon SH; Schiffmann L; Zander T; Büttner R; Hölscher AH; Bruns CJ; Quaas A; Loeser H
BMC Cancer; 2019 Jan; 19(1):38. PubMed ID: 30621632
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathologic features and treatment advances in cancers with HER2 alterations.
Cen S; Liu Z; Pan H; Han W
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188605. PubMed ID: 34358635
[TBL] [Abstract][Full Text] [Related]
34. PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells.
Mangiapane LR; Nicotra A; Turdo A; Gaggianesi M; Bianca P; Di Franco S; Sardina DS; Veschi V; Signore M; Beyes S; Fagnocchi L; Fiori ME; Bongiorno MR; Lo Iacono M; Pillitteri I; Ganduscio G; Gulotta G; Medema JP; Zippo A; Todaro M; De Maria R; Stassi G
Gut; 2022 Jan; 71(1):119-128. PubMed ID: 33436496
[TBL] [Abstract][Full Text] [Related]
35. Enrichment of
Mitra D; Clark JW; Shih HA; Oh KS; Brastianos PK; Wo JY; Strickland MR; Curry WT; Parikh AR; Corcoran RB; Ryan DP; Iafrate AJ; Borger DR; Lennerz JK; Hong TS
Oncologist; 2019 Feb; 24(2):193-201. PubMed ID: 30373904
[TBL] [Abstract][Full Text] [Related]
36. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
Wiedmann M; Feisthammel J; Blüthner T; Tannapfel A; Kamenz T; Kluge A; Mössner J; Caca K
Anticancer Drugs; 2006 Aug; 17(7):783-95. PubMed ID: 16926628
[TBL] [Abstract][Full Text] [Related]
37. Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer.
Shimada Y; Yagi R; Kameyama H; Nagahashi M; Ichikawa H; Tajima Y; Okamura T; Nakano M; Nakano M; Sato Y; Matsuzawa T; Sakata J; Kobayashi T; Nogami H; Maruyama S; Takii Y; Kawasaki T; Homma KI; Izutsu H; Kodama K; Ring JE; Protopopov A; Lyle S; Okuda S; Akazawa K; Wakai T
Hum Pathol; 2017 Aug; 66():1-9. PubMed ID: 28235632
[TBL] [Abstract][Full Text] [Related]
38. Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer.
Parikh A; Atreya C; Korn WM; Venook AP
J Natl Compr Canc Netw; 2017 Jan; 15(1):3-8. PubMed ID: 28040715
[TBL] [Abstract][Full Text] [Related]
39. Treating the HER2 pathway in early and advanced breast cancer.
Pegram MD
Hematol Oncol Clin North Am; 2013 Aug; 27(4):751-65, viii. PubMed ID: 23915743
[TBL] [Abstract][Full Text] [Related]
40. Mind the target: human epidermal growth factor receptor 2 in colorectal cancer.
Saúde-Conde R; Rasschaert G; Bregni G; Hendlisz A; Sclafani F
Curr Opin Oncol; 2022 Jul; 34(4):382-388. PubMed ID: 35730499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]